Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial.
Hui Liu, Yuxin Fan, Yihui Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 1 randomized controlled trial evaluated the pharmacokinetics, pharmacodynamics, and safety of once-weekly insulin efsitora alfa compared to once-daily insulin glargine in Chinese patients with type 2 diabetes. The study involved 31 participants and found that efsitora had a prolonged elimination half-life of approximately 15 days, with comparable glycemic control to glargine.
Key findings
- Efsitora exhibited a prolonged elimination half-life of approximately 15 days.
- Both efsitora and glargine groups showed comparable reductions in fasting glucose.
- TEAEs occurred in 81.0% of efsitora patients and 80.0% of glargine patients, all mild or moderate.
- No treatment-emergent anti-drug antibodies were detected.
Why it matters
The study highlights the potential of once-weekly insulin efsitora alfa to improve treatment adherence in patients with type 2 diabetes, addressing a common challenge in diabetes management. Its comparable efficacy and safety profile to daily insulin glargine may offer a viable alternative for patients.